Choosing the right adjuvant therapy for stage III-IVA endometrial cancer: A comparative analysis of chemoradiotherapy and chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyun Ju | - |
dc.contributor.author | Lee, Joongyo | - |
dc.contributor.author | Lee, Kwang-Beom | - |
dc.contributor.author | Sung, KiHoon | - |
dc.contributor.author | Kim, Yong Bae | - |
dc.contributor.author | Kim, Young Saing | - |
dc.date.accessioned | 2024-03-28T12:30:23Z | - |
dc.date.available | 2024-03-28T12:30:23Z | - |
dc.date.issued | 2024-03 | - |
dc.identifier.issn | 0090-8258 | - |
dc.identifier.issn | 1095-6859 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90819 | - |
dc.description.abstract | Objective. The optimal adjuvant treatment for patients with locally advanced endometrial cancer (EC) remains debatable. We comparatively analyzed recurrence patterns and survival outcomes in patients with stage III-IVA EC treated with adjuvant chemotherapy (CT) exclusively or combined with radiotherapy (CRT). Methods. We retrospectively analyzed 184 patients treated for stage III-IVA EC at 2 tertiary institutions between 2010 and 2021. All patients underwent standard primary surgery and received either CT alone (n = 89) or CRT (n = 95) as an adjuvant treatment. We compared the failure patterns, recurrence -free survival (RFS), and overall survival (OS) between the CT and CRT groups. Results. The median follow-up period was 54.8 months. Most patients underwent pelvic (94.6%) or paraaortic (75.5%) lymphadenectomies. The 5 -year RFS was 69.2% with CRT versus 56.3% with CT (P = 0.038), and 5 -year OS was 86.1% versus 78.9% (P = 0.357). Pelvic and para-aortic recurrence rates were significantly higher in the CT group (pelvic: 29.2%; para-aortic: 20.2%) than in the CRT group (pelvic: 10.5%; para-aortic: 6.3%). The CRT group showed a higher rate of distant recurrence (CRT, 23.2% vs. CT, 14.6%) however, the 5 -year cumulative incidence of distant recurrence was not significantly different between the two groups (CRT, 28% vs. CT, 35%). Conclusions. This study highlights the potential benefits of adjuvant CRT in patients with stage III-IVA EC. The incorporation of molecular classification is necessary to derive optimal personalized adjuvant treatment strategies for this patient population. (c) 2024 Elsevier Inc. All rights reserved. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | - |
dc.title | Choosing the right adjuvant therapy for stage III-IVA endometrial cancer: A comparative analysis of chemoradiotherapy and chemotherapy | - |
dc.type | Article | - |
dc.identifier.wosid | 001171513300001 | - |
dc.identifier.doi | 10.1016/j.ygyno.2024.01.017 | - |
dc.identifier.bibliographicCitation | GYNECOLOGIC ONCOLOGY, v.182, pp 39 - 44 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85184765647 | - |
dc.citation.endPage | 44 | - |
dc.citation.startPage | 39 | - |
dc.citation.title | GYNECOLOGIC ONCOLOGY | - |
dc.citation.volume | 182 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Adjuvant therapy | - |
dc.subject.keywordAuthor | Stage III-IVA endometrial cancer | - |
dc.subject.keywordAuthor | Radiotherapy | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Locally advanced | - |
dc.subject.keywordPlus | PLUS RADIATION | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | WOMEN | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Obstetrics & Gynecology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Obstetrics & Gynecology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.